Oncology PracticePembrolizumab paired with immunostimulator is safe and tolerableJune 15, 2016Genitourinary CancerHead & Neck/Thyroid CancersLung CancerImmuno-oncology
Oncology PracticeImmune agonist, checkpoint inhibitor combo shows good tolerabilityJune 15, 2016Genitourinary CancerBreast CancerLung CancerMelanomaRenal Cell Carcinoma
Oncology PracticeBaseline PSA at midlife predicts lethal prostate cancerJune 13, 2016Genitourinary Cancer
Oncology PracticeAtezolizumab has good showing as first-line therapy in urothelial cancerJune 13, 2016Genitourinary Cancer
Oncology PracticeMyPathway: Targeted therapies show promise in nonindicated tumorsJune 8, 2016GastroenterologyLung CancerBreast CancerGenitourinary CancerHead & Neck/Thyroid CancersMelanomaRare Diseases
Oncology PracticeVIDEO: Immune checkpoint inhibitor is efficacious as first-line therapy for advanced bladder cancerJune 6, 2016Genitourinary Cancer
Oncology PracticeFDA approves atezolizumab for advanced urothelial carcinomaMay 19, 2016Genitourinary Cancer
Oncology PracticeFDA approves lenvatinib for advanced renal cell carcinomaMay 16, 2016Genitourinary CancerRenal Cell Carcinoma
Oncology PracticeNCI: Use of dug wells in New England linked with risk of bladder cancerMay 6, 2016Genitourinary Cancer
The Journal of Community and Supportive OncologyRepeated measures analysis of patient-reported outcomes in prostate cancer after abiraterone acetateApril 27, 2016Genitourinary CancerPatient & Survivor Care
The Journal of Community and Supportive OncologyMore success for immunotherapy with nivolumab approval for metastatic RCCApril 27, 2016Genitourinary CancerImmunotherapy
Oncology PracticePhysician, know thy patient before recommending treatmentApril 14, 2016Genitourinary Cancer
